Japan Signals Readiness to Act on Yen as Intervention Speculation Grows 
South Korean Stocks Tumble as AI Chip Selloff Hits Asian Markets 
US Resumes Dollar Shipments to Iraq After Months-Long Suspension 
Kuaishou Stock Jumps as Kling AI Secures $2 Billion Funding Round 
Asian Currencies Rise as Dollar Weakens; Yen Holds Steady Amid Japan Intervention Watch 
Trump Administration to Launch Voluntary AI Standards for Frontier Models 
Tesla Q2 Deliveries Lift Chinese Auto Suppliers as EV Demand Improves 
New Zealand Consumer Confidence Rises in June as Inflation Expectations Ease 
Brazil to Phase Out Gasoline Subsidy First as Diesel Support Stays Longer 
US Dollar Rises as Fed Rate Outlook Stays Hawkish, Euro Slips and Yen Near 40-Year Low 
Anthropic Restores Claude Fable 5 and Mythos 5 After U.S. Lifts AI Export Controls 
Asian Currencies Stay Under Pressure as Dollar Holds Near 13-Month High Ahead of U.S. Jobs Report 
Oil Prices Slip as Oversupply Concerns and U.S.-Iran Talks Shape Market Outlook 
TetherMax Rebranding Highlights Official Exchange Partnerships as Foundation of Trust 
Suncorp Cuts 2026 Premium Growth Forecast as Australia, New Zealand Markets Weaken 
ShareChat Eyes 2027 IPO After Reaching Operational Profitability, Report Says 
U.S. Dollar Drops as Weak Jobs Data Boosts Fed Pause Bets, Yen Jumps on Intervention Talk 
Abbott Nutrition said last weekend that it had reopened its Sturgis, Michigan plant to resume the production of baby formula. The company hopes that the nationwide shortage of milk will be addressed once it begins the normal production once again.
Abbott Nutrition was able to open its production facility in Michigan after the U.S. Food and Drug Administration (USFDA) had given it the go-ahead to do so. The permit was granted by the agency after the company met the initial requirements as part of a May 16 consent decree.
According to CNBC, Abbott Nutrition will now restart the production of its EleCare baby formula that has been formulated for children who have difficulties digesting other products. The company will also manufacture its other specialty milk and metabolic formulas for infants.
As the company is now able to begin production again, it is hoping to release the first batch of EleCare milk products by June 20. Currently, Abbott is still working to comply with the guidelines set for the resumption of production for its Similac milk line and other infant formulas.
“We understand the urgent need for formula and our top priority is getting high-quality, safe formula into the hands of families across America,” Abbott’s spokesman said in a statement. “We will ramp production as quickly as we can while meeting all requirements.“
It was noted that the issue with the supply of baby formula began in the early stage of the COVID-19 pandemic. However, the situation got worse when Abbott Nutrition’s production facility in Michigan was ordered to close due to contamination. The plant was shut down in February following reports of illnesses in babies after consuming the company-made milk formulas, and two infants have died.
“The FDA is continuing to work diligently to ensure the safe resumption of production of infant formula at Abbott Nutrition’s Sturgis, Michigan, facility,” the USFDA commented with regards to Abbot’s plant reopening. “The agency expects that the measures and steps it is taking, and the potential for Abbott Nutrition’s Sturgis, Michigan, facility, to safely resume production in the near-term, will mean more and more infant formula is either on the way to or already on store shelves moving forward.”
